12:00 AM
Mar 11, 2013
 |  BC Week In Review  |  Clinical News  |  Regulatory

Feiba NF regulatory update

Baxter submitted an sBLA to FDA for Feiba NF anti-inhibitor coagulant complex as a prophylactic treatment in hemophilia A and B patients with inhibitors. Feiba NF is already marketed in the U.S....

Read the full 136 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >